Evidence map›Paper›PMID 40949906›Full record

ArticleTranslational pediatrics2025

Real-life data on the efficacy and safety of letermovir for cytomegalovirus prophylaxis in high-risk pediatric patients: a single-center analysis.

Meng Zhang, Ningning Chen, Yanhui Luo, Chenguang Jia, Jie Zheng, Lixiao Cai, Pan Zhang, Yuanfang Jing, Wei Yang, Maoquan Qin and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Meng Zhang *Department of Stem Cell Transplantation, Hematology Center, National Key Clinical Discipline of Pediatric Hematology, National Key Discipline of Pediatrics, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Ningning Chen *Department of Hematology, Baoding Hospital of Beijing Children's Hospital, Capital Medical University, Baoding, China.
Yanhui Luo *Department of Stem Cell Transplantation, Hematology Center, National Key Clinical Discipline of Pediatric Hematology, National Key Discipline of Pediatrics, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Chenguang JiaDepartment of Stem Cell Transplantation, Hematology Center, National Key Clinical Discipline of Pediatric Hematology, National Key Discipline of Pediatrics, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Jie ZhengDepartment of Stem Cell Transplantation, Hematology Center, National Key Clinical Discipline of Pediatric Hematology, National Key Discipline of Pediatrics, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Lixiao CaiDepartment of Hematology, Baoding Hospital of Beijing Children's Hospital, Capital Medical University, Baoding, China.
Pan ZhangDepartment of Hematology, Baoding Hospital of Beijing Children's Hospital, Capital Medical University, Baoding, China.
Yuanfang JingDepartment of Stem Cell Transplantation, Hematology Center, National Key Clinical Discipline of Pediatric Hematology, National Key Discipline of Pediatrics, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Wei YangDepartment of Stem Cell Transplantation, Hematology Center, National Key Clinical Discipline of Pediatric Hematology, National Key Discipline of Pediatrics, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Maoquan QinDepartment of Stem Cell Transplantation, Hematology Center, National Key Clinical Discipline of Pediatric Hematology, National Key Discipline of Pediatrics, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Guanghua ZhuDepartment of Stem Cell Transplantation, Hematology Center, National Key Clinical Discipline of Pediatric Hematology, National Key Discipline of Pediatrics, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Jun YangDepartment of Stem Cell Transplantation, Hematology Center, National Key Clinical Discipline of Pediatric Hematology, National Key Discipline of Pediatrics, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Letermovir (LET) is approved for the prophylaxis of cytomegalovirus (CMV) infection and disease in adult hematopoietic stem cell transplantation (HSCT) patients up to day 100. The use of LET in the pediatric HSCT population lacks extensive real-world research, especially for high-risk pediatric patients with CMV reactivation. The aim of our study was retrospectively analyzed the efficacy and safety of LET in high-risk pediatric patients with CMV activation, and conducted a preliminary exploration of its duration of use. Methods: This was a single-center, retrospective study. A total of 123 patients under 18 years of age who were at high risk of CMV reactivation were included, with 61 of them receiving LET for prophylaxis. The median duration was 100 days (ranging from 52 to 298 days). The primary endpoint was the proportion of patients with clinically significant CMV infection (CsCMVi) at 24 weeks post-transplantation. The secondary endpoints were the proportion of patients with CsCMVi before week 14 and the timing of CMV infection. Additionally, we also assessed related adverse reactions. Results: The proportion of CMV reactivation at 24 weeks post-transplantation in the LET group was significantly lower than that in the control group (8.20% Conclusions: LET can effectively prevent CMV reactivation in patients under 18 years of age and demonstrates good safety. For pediatric patients at high risk of CMV reactivation, extending the duration of prophylaxis beyond 100 days may be beneficial.

Indexed as

cytomegalovirus reactivation (CMV reactivation)hematopoietic stem cell transplantation (HSCT)high-riskLetermovir (LET)pediatric patients

Identifiers

PMID40949906
PMCPMC12433127

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.